Skip to main content
    M

    Monte Rosa Therapeutics Inc (GLUE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.07
    -0.09 (-0.98%)

    Market Cap: $800.67M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Monte Rosa Therapeutics Inc (GLUE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Monte Rosa Therapeutics (GLUE) has a market cap of $800.67M and an enterprise value of $755.49M. It kept -186.24% of revenue as net income over the last 12 months. Its share count is up 23.54% from a year earlier.

    Total Valuation

    Enterprise value is 5.64% below the market cap, as cash exceeds debt.

    Market Cap$800.67M
    Enterprise Value$755.49M
    Latest price (Nov 17, 2026)$9.07

    Key Dates

    The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 15, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.31% in the quarter ended Sep 30, 2026 and grew 11.41% a year over 2 years.

    Shares Outstanding101.79M
    Shares Change (YoY)+23.54%
    Shares Change (QoQ)+0.31%
    Share Count Growth (2Y CAGR)+11.41%

    Valuation Ratios

    Sales and book value multiples are 13.1x and 1.9x. Its year-end P/S ranged from 5.9x to 36.8x from 2023 to 2025.

    P/S Ratio13.1x
    Forward P/S7.8x
    P/B Ratio1.9x

    Valuation history and multiples

    Price Statistics

    The stock is down 36.84% over 52 weeks and trades 18.29% below its 50-day average.

    Beta (1Y)0.93
    52-Week Change-36.84%
    1-Month Change-14.92%
    3-Month Change-42.49%
    6-Month Change-48.41%
    5-Year Change-54.12%
    Total Return (1Y)-36.84%
    Total Return (3Y CAGR)+39.37%
    Total Return (5Y CAGR)-15.65%
    Return vs SPY (1Y)-45.74%
    Max Drawdown (1Y)-64.16%
    Max Drawdown (3Y)-64.29%
    Sharpe Ratio (1Y)-0.54
    Correlation with SPY (1Y)0.17
    50-Day Average$11.10
    200-Day Average$16.63
    52-Week Range$8.95 to $25.77
    RSI (14 Days)30.9
    Average Volume (20 Days)1.32M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 10.32x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio10.32x
    Quick Ratio10.32x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -26.39% over the last 12 months, against a 5-year average of -37.19%.

    Return on Equity (ROE)-26.39%
    Return on Assets (ROA)-18.77%
    ROE (5Y Average)-37.19%
    ROA (5Y Average)-24.32%
    ROIC (5Y Average)-21.97%
    Asset Turnover0.12x
    Receivables Turnover11.21x

    Scores

    GLUE has an Altman Z-Score of 2.00, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score2.00
    Altman Z ZoneGrey
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $70.33M over the last 12 months is down 61.26% from the 12 months before.

    Revenue$70.33M
    Revenue Growth (YoY)-61.26%
    Gross Profit$70.33M
    Operating Income-$150.82M
    Pretax Income-$129.94M
    Net Income-$130.97M
    Reported EPS (TTM)-$1.40

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 71.12% of the $697.73M in total assets.

    Cash and Equivalents$45.18M
    Total Debt$0
    Net Cash$45.18M
    Net Cash Per Share$0.44
    Working Capital$578.02M
    Shareholder Equity$496.21M
    Book Value Per Share$4.87
    Total Assets$697.73M
    Total Liabilities$201.52M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $8.92M of capital spending, operating cash flow left -$174.39M of free cash flow.

    Operating Cash Flow-$165.47M
    Capital Expenditures$8.92M
    Free Cash Flow-$174.39M
    FCF Per Share-$2.04
    Depreciation and Amortization$8.18M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -214.46%.

    Gross Margin100.00%
    Operating Margin-214.46%
    Pretax Margin-184.77%
    Net Margin-186.24%
    FCF Margin-247.98%

    Growth

    Book Value Per Share Growth (2Y CAGR)+6.27%
    Tangible Book Per Share Growth (2Y CAGR)+6.27%

    Revenue and profit by year

    Dividends and Yields

    GLUE does not pay a dividend. Its free cash flow yield is -18.89%.

    FCF Yield-18.89%
    Buyback Yield-2.59%
    Shareholder Yield-2.59%

    Peer Position

    Against 6 similar companies, GLUE has the 5th highest P/S.

    P/S Ratio13.1x vs 35.2x median
    Revenue Growth (Trailing 4 Quarters, YoY)-61.26% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -29.10% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-29.10%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GLUE

    What is GLUE's market cap?

    Monte Rosa Therapeutics has a market cap of $800.67M. Its enterprise value, which adds debt and subtracts cash, is $755.49M.

    How many shares of GLUE are outstanding?

    Monte Rosa Therapeutics has 101.79M shares outstanding. The count is up 23.54% from a year earlier.

    Does GLUE pay a dividend?

    No. Monte Rosa Therapeutics does not pay a dividend.

    How much debt does GLUE have?

    Monte Rosa Therapeutics has $0 of total debt and $45.18M of cash and equivalents, a net cash position of $45.18M.